Home  |  Contact

Cellosaurus VM-CUB-3 (CVCL_9830)

Cell line name VM-CUB-3
Synonyms VM-CUB3; VMCUB-3; VMCUB3; VMCub3; VM Cub 3; VM-CUB-III; VMCUBIII; CUB III; CUBIII
Accession CVCL_9830
Resource Identification Initiative To cite this cell line use: VM-CUB-3 (RRID:CVCL_9830)
Comments Problematic cell line: Partially contaminated. Some stocks are contaminated by VM-CUB-1 (PubMed=3708594; PubMed=20143388). Although PubMed=26621286 shows it to be different from VM-CUB-1.
Part of: BLA-40 bladder carcinoma cell line panel.
Part of: UBC-40 urothelial bladder cancer cell line index.
Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00102.
Doubling time: 26 hours (PubMed=3708594).
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations TERT c.228C>T (-124C>T); in promoter (PubMed=24035680).
Homozygous for TP53 p.Pro278Leu (c.833C>T) (PubMed=27270441).
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Category Cancer cell line
STR profile Source(s): PubMed=27270441

Markers:
AmelogeninX
CSF1PO12
D13S3179,12
D16S53912
D5S81811
D7S8208,9
TH019.3
TPOX8
vWA16
Web pages http://iclac.org/wp-content/uploads/Cross-Contaminations_v9_distribution.xlsx
https://www.synapse.org/UC25
Publications

PubMed=571047
Fogh J.
Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors.
Natl. Cancer Inst. Monogr. 49:5-9(1978)

PubMed=6244232
Williams R.D.
Human urologic cancer cell lines.
Invest. Urol. 17:359-363(1980)

PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

PubMed=6220172
Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3708594
Masters J.R.W., Hepburn P.J., Walker L., Highman W.J., Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.R., Franks L.M.
Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines.
Cancer Res. 46:3630-3636(1986)

PubMed=15846775; DOI=10.1002/gcc.20166
Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J., Knowles M.A.
Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro.
Genes Chromosomes Cancer 43:315-328(2005)

PubMed=16885334; DOI=10.1158/0008-5472.CAN-06-1182
Lopez-Knowles E., Hernandez S., Malats N., Kogevinas M., Lloreta J., Carrato A., Tardon A., Serra C., Real F.X.
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
Cancer Res. 66:7401-7404(2006)

PubMed=20143388; DOI=10.1002/ijc.25242
Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A., MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R., Freshney R.I.
Check your cultures! A list of cross-contaminated or misidentified cell lines.
Int. J. Cancer 127:1-8(2010)

PubMed=24367658; DOI=10.1371/journal.pone.0084411
Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H., Knowles M.A.
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
PLoS ONE 8:E84411-E84411(2013)

PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057
Hurst C.D., Platt F.M., Knowles M.A.
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Eur. Urol. 65:367-369(2014)

PubMed=25997541; DOI=10.1186/s12864-015-1450-3
Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B., Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G., Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D., Chanock S., Valencia A., Real F.X.
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
BMC Genomics 16:403-403(2015)

PubMed=26621286; DOI=10.1186/s12864-015-2227-4
Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B., Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G., Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D., Chanock S., Valencia A., Real F.X.
Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
BMC Genomics 16:1019-1019(2015)

PubMed=27270441; DOI=10.1038/onc.2016.172
Nickerson M.L., Witte N., Im K.M., Turan S., Owens C., Misner K., Tsang S.X., Cai Z., Wu S., Dean M., Costello J.C., Theodorescu D.
Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.
Oncogene 36:35-46(2017)

PubMed=29732388; DOI=10.3233/BLC-180167
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)

Cross-references
Cell line collections ATCC; HTB-6 - Discontinued
Biological sample resources BioSample; SAMN03152040
Gene expression databases GEO; GSM136263
GEO; GSM1574580
Other Wikidata; Q54993215
Polymorphism and mutation databases Cosmic; 925826
Cosmic; 1016888
Cosmic; 1046679
Cosmic; 1285135
Cosmic; 1285994
Cosmic; 1938425
Cosmic; 2050472
Cosmic; 2057463
Cosmic; 2444225
Cosmic; 2212697